BR112013032610A2 - formulações de estilbeno fluorado adequadas para imagiologia pet - Google Patents

formulações de estilbeno fluorado adequadas para imagiologia pet

Info

Publication number
BR112013032610A2
BR112013032610A2 BR112013032610A BR112013032610A BR112013032610A2 BR 112013032610 A2 BR112013032610 A2 BR 112013032610A2 BR 112013032610 A BR112013032610 A BR 112013032610A BR 112013032610 A BR112013032610 A BR 112013032610A BR 112013032610 A2 BR112013032610 A2 BR 112013032610A2
Authority
BR
Brazil
Prior art keywords
stilbene
pet imaging
formulations suitable
fluorinated
formulations
Prior art date
Application number
BR112013032610A
Other languages
English (en)
Other versions
BR112013032610B1 (pt
Inventor
Andreas Burkhard
Annett Richter
Carsten Olbrich
Michael Krause
Rainer Braun
Original Assignee
Piramal Imaging Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Imaging Sa filed Critical Piramal Imaging Sa
Publication of BR112013032610A2 publication Critical patent/BR112013032610A2/pt
Publication of BR112013032610B1 publication Critical patent/BR112013032610B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo patente de invenção: "formulações de estilbeno fluorado adequadas para imagiologia pet". a presente invenção refere-se à formulações de estilbeno com capacidade ligante a beta amiloide lipofílico e mais particularmente a formulações que são capazes de ser administradas parenteralmente, por exemplo, de forma intravenosa, em que o estilbeno com capacidade ligante a beta amiloide lipofílico é um estilbeno fluorado. ademais, a invenção é direcionada a um método para a filtração estéril de formulações adequadas para imagiologia pet de mamíferos de acordo com a invenção.
BR112013032610-7A 2011-06-21 2012-06-21 Formulações de estilbeno fluorado adequadas para imagiologia pet, e seus métodos de preparação, obtenção e filtração estéril BR112013032610B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11005047 2011-06-21
EP11005047.3 2011-06-21
PCT/EP2012/062034 WO2012175641A1 (en) 2011-06-21 2012-06-21 Formulations of fluorinated stilbene suitable for pet imaging

Publications (2)

Publication Number Publication Date
BR112013032610A2 true BR112013032610A2 (pt) 2017-01-24
BR112013032610B1 BR112013032610B1 (pt) 2022-05-31

Family

ID=46354330

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013032610-7A BR112013032610B1 (pt) 2011-06-21 2012-06-21 Formulações de estilbeno fluorado adequadas para imagiologia pet, e seus métodos de preparação, obtenção e filtração estéril

Country Status (21)

Country Link
US (1) US9308284B2 (pt)
EP (1) EP2723394B1 (pt)
JP (1) JP6081997B2 (pt)
KR (1) KR101869129B1 (pt)
CN (2) CN105833303A (pt)
AU (1) AU2012274076B2 (pt)
BR (1) BR112013032610B1 (pt)
CA (1) CA2839961C (pt)
DK (1) DK2723394T3 (pt)
ES (1) ES2683818T3 (pt)
HK (2) HK1197031A1 (pt)
HR (1) HRP20181081T1 (pt)
HU (1) HUE039909T2 (pt)
IL (1) IL230042A (pt)
MX (1) MX344954B (pt)
MY (1) MY183997A (pt)
PL (1) PL2723394T3 (pt)
PT (1) PT2723394T (pt)
RU (1) RU2623867C2 (pt)
SI (1) SI2723394T1 (pt)
WO (1) WO2012175641A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6207588B2 (ja) 2012-04-10 2017-10-04 ランセウス メディカル イメージング， インコーポレイテッド 放射性薬剤合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID26102A (id) * 1998-02-20 2000-11-23 Ciba Sc Holding Ag Proses pembuatan senyawa-senyawa stilbena
DE10012120A1 (de) * 2000-03-13 2001-09-27 Ktb Tumorforschungs Gmbh Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel
JP4436928B2 (ja) 2001-08-27 2010-03-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア スチルベン誘導体、およびアミロイド斑の結合および画像化のためのその使用
SI2213652T1 (sl) * 2004-12-17 2015-03-31 The Trustees Of The University Of Pennsylvania Derivati stilbena in njihova uporaba za vezavo in prikaz amiloidnih plakov
EA023014B1 (ru) * 2008-12-31 2016-04-29 Эвид Рэйдиофармасьютикалз, Инк. Синтез стирилпиридинов, меченных радиоактивным изотопомf, из предшественников тозилата и их стабильные фармацевтические композиции
US8658129B2 (en) * 2009-06-04 2014-02-25 General Electric Company Agents and methods for the imaging of myelin basic protein
KR101718164B1 (ko) * 2009-12-17 2017-03-20 엘지전자 주식회사 인증 절차를 고려한 핸드오버 수행 방법 및 장치
EP2515948A1 (en) * 2009-12-23 2012-10-31 Piramal Imaging SA Formulations suitable for pet imaging with hydrophobic pet agents
BR112012030935B1 (pt) 2010-04-06 2020-11-17 Life Molecular Imaging Sa método para a produção de ligantes de beta-amiloide marcados com f-18

Also Published As

Publication number Publication date
EP2723394B1 (en) 2018-05-23
CN103841994A (zh) 2014-06-04
IL230042A (en) 2017-06-29
MX2013015074A (es) 2014-11-10
BR112013032610B1 (pt) 2022-05-31
ES2683818T3 (es) 2018-09-28
CA2839961A1 (en) 2012-12-27
JP2014517054A (ja) 2014-07-17
US9308284B2 (en) 2016-04-12
JP6081997B2 (ja) 2017-02-15
RU2014101557A (ru) 2015-07-27
CN103841994B (zh) 2016-05-11
RU2623867C2 (ru) 2017-06-29
MX344954B (es) 2017-01-12
SI2723394T1 (sl) 2018-10-30
HUE039909T2 (hu) 2019-02-28
DK2723394T3 (en) 2018-08-13
MY183997A (en) 2021-03-17
NZ618977A (en) 2015-07-31
KR101869129B1 (ko) 2018-06-19
KR20140061347A (ko) 2014-05-21
HRP20181081T1 (hr) 2018-09-21
EP2723394A1 (en) 2014-04-30
PL2723394T3 (pl) 2018-11-30
WO2012175641A1 (en) 2012-12-27
HK1197031A1 (zh) 2015-01-02
CN105833303A (zh) 2016-08-10
CA2839961C (en) 2019-08-13
PT2723394T (pt) 2018-07-30
AU2012274076B2 (en) 2017-06-15
US20140241986A1 (en) 2014-08-28
HK1225648A1 (zh) 2017-09-15
AU2012274076A1 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
CL2017003288A1 (es) Métodos para tratar o prevenir enfermedades relacionadas con el colesterol (divisional solicitud 201303214)
BR112014012822A8 (pt) Radioligantes rotulados com flúor-18 e carbono-11 para imagiologia por tomografia por emissão de pósitrons (pet) para lrrk2
DOP2014000260A (es) Compuestos d-aminoácidos para enfermedad hepática
DOP2012000243A (es) Compuestos de sililo tricíclicos fusionados y uso de los mismos en la fabricación de medicamentos útiles en el tratamiento de enfermedades virales
CL2014000806A1 (es) Compuestos derivados de 1-arilcarbonil-4-oxi-piperidino; composicion farmaceutica que los comprende; uso para la prevencion o el tratamiento de enfermedades neurodegenerativas tales como enfermedad de alzheimer, enfermedad de parkinson, enfermedad de huntington o esclerosis multiple.
BR112014002946A2 (pt) sistema de travamento mecânico para painéis de piso
BR112013030599A2 (pt) núcleo absorvente para artigos absorventes descartáveis
BR112015010791A2 (pt) moduladores de gpr40 de di-hidropirazol
GT201500334A (es) Compuestos de 3,4- dihidroisoquinolin-2-(1h)-ilo
BR112013030894A2 (pt) moduladores do sistema imune
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
BR112014019667A2 (pt) formulação de anticorpo abeta
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
UY34701A (es) Formas sólidas de un profármaco de nucleótidos de tiofosforamidato
BR112014006271A2 (pt) composições farmacêuticas
BR112015010779A2 (pt) moduladores de di-hidropirazol gpr40
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
SV2016005153A (es) Compuestos y composiciones como inhibidores de la mek
BR112014000516A2 (pt) sistema de travamento mecânico para painéis de piso
BR112013030264A2 (pt) ácidos acéticos de benzociclohepteno
DOP2014000034A (es) Compuestos de benzofurano para su uso en el tratamiento de infecciones por el virus de hepatitis c (hcv)
GT201400242A (es) "nuevos compuestos de pirazol"
CO7131387A2 (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
BR112015003957A2 (pt) alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria
CL2013003646A1 (es) Compuestos derivados de trans-1-(3s.1r)-6-cloro-3-fenilindan-1-il)-1,2,2-trimetilpiperazina deuterados, con actividad en los receptores 5ht2, d1 y d2; proceso de preparacion; compuesto intermediario; composicion y combinacion farmaceutica; y su uso para el tratamiento de la psicosis, entre otros.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25D Requested change of name of applicant approved

Owner name: LIFE MOLECULAR IMAGING SA (CH)

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/06/2012, OBSERVADAS AS CONDICOES LEGAIS

B25A Requested transfer of rights approved

Owner name: LIFE MOLECULAR IMAGING LIMITED (GB)

B25G Requested change of headquarter approved

Owner name: LIFE MOLECULAR IMAGING LIMITED (GB)